Last reviewed · How we verify
Riamet®
At a glance
| Generic name | Riamet® |
|---|---|
| Also known as | artemether and lumefantrine combination therapy |
| Sponsor | sigma-tau i.f.r. S.p.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum (PHASE1)
- Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria (PHASE1)
- A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (PHASE1)
- Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites (PHASE1)
- Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects (PHASE1)
- Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria (PHASE3)
- Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria (PHASE4)
- Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Riamet® CI brief — competitive landscape report
- Riamet® updates RSS · CI watch RSS
- sigma-tau i.f.r. S.p.A. portfolio CI